Evaluation Of High Sensitivity C - Reactive Protein and Serum Lipid Profile In Prehypertension and Essential Hypertension
CRP in hypertension
Keywords:
Hypertension, hsCRP, Lipid profileAbstract
Background: Hypertension is a common, asymptomatic, readily detectable disease that leads to lethal complications if left untreated. Vascular inflammation may be involved in both the initiation and development of hypertension that is evident from the elevated levels of inflammatory markers like Tumor necrosis factor-α, Interleukin-6 and C-reactive protein (CRP) found in people with hypertension with no evidence of cardiovascular disease. hsCRP is associated with an increased risk of incident hypertension at all baseline blood pressures and among individuals without traditional coronary heart disease risk factors. Objectives: The present cross-sectional study was an attempt to evaluate the relationship of serum hsCRP levels and serum Lipid profile in prehypertensives and hypertensive. Material & methods: The study group included thirty diagnosed cases of prehypertension and hypertension each, attending medicine OPD at a tertiary care hospital. A healthy group of normotensive volunteers were taken as controls. Fasting blood samples were collected for measurement of serum lipid profile and hsCRP (by CLIA).Results: There was statistically significant rise in hsCRP levels in hypertensives as compared to controls and normotensives (p<0.001). The concentration of cholesterol, triglycerides and LDL-C were significantly high in hypertensives as compared with normotensives (p<0.001). Conclusion: Findings of higher levels of hsCRP in hypertension along with atherogenic lipid profile suggests that elevated hsCRP and hypertension can be independent determinants of cardiovascular risk.
References
Disease. Harrison’s Principles of Internal
Medicine.16th Edition. Part Eight; Section Four;
Chapter 246;1463-70.
2. Harrison’s Principles of Internal Medicine. 18th
edition. Chapter 247:2042-59.
3. LiJian-jun. Inflammation in hypertension:
primary evidence. Chin Med J 2006;119:1215-
21.
4. Pauleto P, Rattazzi M. Inflammation and
Hypertension: the search for a link. Nephrol Dial
Transplant 2006; 21: 850-53.
5. Bas C. van Bussel, Fleur Schouten, Ronald M.
Henry, et al. Endothelial dysfunction and lowgrade
Inflammation areassociated with greater
arterial stiffness over a 6-year period.
Hypertension. 2011;58:588-595.
6. Bautista LE, Lopez- Jaramillo, Patricio, et al. Is CReactive
Protein an independent risk factor for
essential hypertension? Journal of
Hypertension. 2001; 19 (5): 857-61.
7. Chobanian AV et al. Seventh report of the Joint
National Committee on Prevention, Detection,
Evaluation and Treatment of High blood
pressure. Hypertension. 2003;42:1206-52
8. T. Nieman, Chemiluminescence: Theory and
Instrumentation, Overview. In Encyclopedia of
analytical science, Academic press, Ornaldo,
608-613 (1995).
9. Nader Rifai and G. Russell Warnick. Lipids,
Lipoproteins, apolipoproteins and other
cardiovascular risk factors.Teitz. Textbook of
Clinical Chemistry. 4th Edition. Section IV.
Chapter 26. Pages 943-48.
10. Pisani T, Gebski CP, Leary ET, et al. Accurate
determination of Low-Density Lipoprotein
Cholesterol Assay. Arch Pathol Lab Med,
1995;119:1127
11. Ki Chul Sung, Jung YulSuh, Bum Soo Kim, et al.
High Sensitivity C- Reactive Protein as an
independent risk factor for essential
hypertension. American Journal of
Hypertension. 2003; 16:429-33.
12. Sesso HD, Buring JE, Rifai N, et al. C-Reactive
Protein and risk of developing hypertension.
JAMA. 2003;290(22):2945-51.
13. Bautista LE, Vera LM, Arenas IA and Gamarra G.
Independent association between inflammatory
markers (C-reactive protein, IL-6 and TNF-α) and
essential hypertension. Journal of Human
Hypertension. 2005;19:149-154.
14. Chrysohoou C, Pitsavos C, Demosthenes B, et al.
The ATTICA study: Association between
prehypertension status and inflammatory
markers related to atherosclerotic disease.
American Journal of Hypertension.
2004;17:568-73.
15. AE Shutte, D van Vuuren, JM van Rooyen, et al.
Inflammation, Obesity and Cardiovascular
function in African and Caucasian women from
South Africa: the POWIRS study. Journal of
Human Hypertension. 2006;20:850-859.
16. Lu Wang, JoAnn Manson, J. MichaealGaziano,
Simin Lu, Barbara Cochrane et al. Circulating
inflammatory and endothelial markers and risk
of hypertension in white and black postmenopausal
women. Clinical Chemistry.
2011;57(5):729-736.
17. Lopes HF, Silva HB, Saores JA et al. Lipid
metabolism alterations in normotensive
subjects with positive family history of
hypertension. Hypertension 1997;30:629-31.
18. Giovanni de Simone, Richard B. Devereux,
Marcello Chinali et al. Risk Factors for Arterial
Hypertension in
Adults With Initial Optimal Blood Pressure: The
Strong Heart Study. Hypertension. 2006;47:162-
167
19. Dyer AR, Liu K, Walsh M, et al. Ten year
incidence of elevated blood pressure and its
predictors: the CARDIA study. Coronary ArteryRisk Development in (young) adults. J Hum
Hypertens. 1999;13:13-21.
20. Rasouli M and Kiasari M. Interations of serum
hsCRP with apoB, apoB/AI ratio and some
components of metabolic syndrome amplify the
predictive values for coronary artery disease.
ClinBiochem. 2006;39(10):971-77.
21. Nah EH and Kim HC. Comparison of
cardiovascular risk factors between
normotension and prehypertension. Korean J
Lab Med. 2007;27(5):377-81.
22. Marina de Marco, Giovanni de Simone, Mary J.
Roma,n, et al. Cardiovascular and metabolic
predictors of progression of prehypertension
into hypertension: The Strong Heart Study.
Hypertension. 2009;54:974-80.
23. SubodhVerma, Shu-Hong Li,Mitesh V.
Badiwala,et al. Endothelin Antagonism and
Interleukin-6 Inhibition Attenuate the
Proatherogenic Effects of C-Reactive
Protein.Circulation. 2002;105:1890-1896
24. Sridevi Devaraj, Dan yan xu, Ishwarlal Jialal. Creactive
protein increases plasminogen
activator inhibitor-1 expression and activity in
human aortic endothelial cells implications for
the metabolic syndrome and atherothrombosis,
Circulation. 2003;107:398-404.
25. Chao-Hung Wang, Shu-Hong Li, Richard D.
Weisel, Paul W.M. Fedak, Aaron S. Dumont,
Paul Szmitko, et al. C-Reactive
ProteinUpregulates Angiotensin Type 1
Receptors in Vascular Smooth Muscle.
Circulation. 2003;107:1783-1790.
26. Pietri P, Vyssoulis G, Vlachopoulos C, et al.
Relationship between low-grade inflammation
and arterial stiffness in patients with essential
hypertension. J Hypertens.2006;24(11):2231-8.
27. Kampus P, Muda P, Kals J, et al. The relationship
between inflammation and arterial stiffness in
patients with essential hypertension. Int J
Cardiol 2006;112(1):46-51.
28. Kim JS, Kang TS, Kim JB, et al. Significant
association of C-reactive protein with arterial
stiffness in treated non-diabetic hypertensive
patients. Atherosclerosis. 2007;192(2):401-6.
